Mubadala Bio has announced the launch of dydrogesterone through its subsidiary, Bioventure Healthcare, marking a further expansion of the company’s women’s health portfolio. The announcement was made in Abu Dhabi on January 26, 2026, and reflects the group’s continued focus on healthcare manufacturing within the UAE.
Dydrogesterone is a synthetic form of progesterone and is widely used to support hormone balance in women. The therapy is commonly prescribed for a range of fertility-related conditions as well as certain menstrual disorders, making it a well-established treatment option in reproductive healthcare.
The introduction of the medication comes at a time when fertility and reproductive health are receiving increased attention globally. Changing demographics and broader societal trends have brought renewed focus on the availability of trusted and proven therapies, particularly those that support women’s health outcomes.
Commenting on the launch, Dr. Bakheet Al Katheeri, CEO of Mubadala’s UAE Investments Platform and Chairman of Mubadala Bio, said: “This milestone reflects Mubadala’s long-term commitment to building a national life sciences champion. Producing highly needed medical therapies locally strengthens the UAE’s pharmaceutical capabilities while supporting national health priorities.”
Dr. Essam Mohamed, CEO of Mubadala Bio, highlighted the importance of local manufacturing in improving access to treatment. He said: “At Mubadala Bio, we are supporting the life sciences ecosystem in the UAE by enhancing drug security and expanding access to highly demanded treatments. The local production of this medication aligns with our mission to provide better health, closer for all.”
Hamad Husein Al Marzooqi, Deputy CEO of Mubadala Bio, also pointed to the broader social impact of the move. “Women’s health is one of our main priorities and is central to the wellbeing of our society. By bringing the production of this essential treatment closer to home, we are improving access to key medications for women across the UAE,” he said.
The local production of dydrogesterone is seen as both a strategic development for the UAE’s pharmaceutical sector and a timely step in addressing women’s healthcare needs across the country.
About Mubadala Bio
Mubadala Bio is a life sciences company dedicated to pursuing better health outcomes for the UAE and beyond. As a catalyst for progress and innovation, we are accelerating the growth of the life sciences ecosystem by enhancing drug security and expanding access to affordable, essential treatments.
Operating through two core verticals, Integrated Biopharma and Pharma Logistics, we are advancing local pharmaceutical manufacturing while ensuring timely access to critical and lifesaving medications. With a growing footprint across the UAE, Asia, Africa, and Europe, we are driving impact both locally and globally.
Our portfolio focuses on key therapy areas that address some of the world’s most pressing health needs, supporting the full continuum of care, from prevention and diagnosis to treatment, ongoing support, and complementary medicine. Headquartered in Abu Dhabi and wholly owned by Mubadala Investment Company, we are fostering innovation, cultivating local talent, and helping build a knowledge-based economy – delivering better health, closer for all.
Learn more at www.mubadalabio.ae
